The UK has recently witnessed a significant breakthrough in treating rare blood cancers with the introduction of the Polivy drug. This innovative medication can improve survival rates for thousands of patients battling diffuse large B-cell lymphoma, an aggressive and life-threatening type of blood cancer. With approximately 5,000 Britons diagnosed with the condition each year, Polivy offers new hope for improved treatment outcomes and a better quality of life for those affected.
The impact of the Polivy drug in the UK has been nothing short of transformative. Approved by the National Institute For Health and Care Excellence (NICE) after extensive studies, the drug has demonstrated remarkable results in reducing the risk of relapse in patients with diffuse large B-cell lymphoma. As a result, Polivy has been hailed as a “game changer” by leading blood cancer experts, signalling a significant milestone in the fight against this devastating disease.
Table of Contents
What is Polivy?
Polivy (polatuzumab vedotin) is an innovative antibody-drug conjugate designed to target and destroy cancer cells from the inside. By attaching a chemotherapy drug to a specific antibody, Polivy can deliver a powerful, targeted treatment directly to the cancer cells, minimizing damage to healthy cells and reducing the risk of relapse.
What Does it Cure?
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, cancer originating from white blood cells called lymphocytes. This aggressive form of blood cancer can develop rapidly and requires prompt and effective treatment to improve patients’ chances of survival.
Understanding the risk factors for diffuse large B-cell lymphoma (DLBCL) can help individuals and healthcare professionals take appropriate preventive measures and detect early disease.
The following are some of the main risk factors for DLBCL:
The prevalence of DLBCL increases with age, and it is more commonly diagnosed in older adults. Although the condition can affect anyone, the risk is noticeably higher in people around 70.
- Weakened Immune System
A weakened immune system can increase the likelihood of developing DLBCL. Individuals with immunodeficiency disorders, those who have undergone organ transplants, or those taking immunosuppressive medications may be at a higher risk.
- Genetic Factors
Certain inherited genetic factors can contribute to an increased risk of DLBCL. Researchers are still working to identify specific genes that may be associated with the development of this blood cancer.
- Exposure to Harmful Substances
Prolonged or frequent exposure to harmful substances such as pesticides and solvents can increase the risk of DLBCL. These substances may disrupt normal cell functioning and contribute to the development of cancerous cells.
Some viral and bacterial infections, such as the Epstein-Barr virus and Helicobacter pylori, have been linked to an increased risk of DLBCL. These infections can cause chronic inflammation, which may contribute to the development of cancerous cells.
A Promising Treatment for Diffuse Large B-Cell Lymphoma, Study Finds
Polivy has been a significant breakthrough in treating patients with diffuse large B-cell lymphoma. According to a study published in The New England Journal of Medicine, the average relapse rate in patients given Polivy dropped by a quarter in the two years following treatment. Moreover, some patients with non-germinal centre B-cell lymphoma experienced an even greater benefit, with the chance of relapse decreasing by two-thirds.
The National Institute For Health and Care Excellence (NICE) has approved Polivy for use in the NHS after recognizing its substantial benefits compared to existing treatments. The approval of this innovative antibody-drug conjugate further underscores the potential for Polivy to revolutionize the treatment landscape for the approximately 5,000 Britons who develop diffuse large B-cell lymphoma each year, offering renewed hope for patients and their families.
Tips to Avoid Blood Diseases
Blood diseases can significantly impact an individual’s health and quality of life. While some factors contributing to these conditions may be beyond our control, adopting certain lifestyle practices can help reduce the risk of developing blood diseases or improve overall health.
Here are some tips to consider:
- Maintain a Healthy Diet
A balanced diet that includes fruits, vegetables, whole grains, lean proteins, and healthy fats can provide essential nutrients to support your immune system and overall health. Limiting processed foods and added sugars can help reduce inflammation and maintain a healthy weight.
- Exercise Regularly
Regular physical activity can help improve circulation, boost the immune system, and lower the risk of chronic diseases. Aim for at least 150 minutes of moderate or 75 minutes of vigorous-intensity exercise per week.
- Avoid and Limit Alcohol Consumption
Tobacco use and excessive alcohol consumption can wreak havoc on the immune system and increase the risk of blood diseases. Quitting smoking and limiting alcohol consumption can significantly lower the risk of various health problems, including blood disorders.
- Get Regular Checkups and Screenings
Early detection and treatment of blood diseases can greatly improve outcomes. Consult your healthcare provider about the appropriate screening tests for your age and risk factors, and schedule regular checkups to monitor your overall health.
- Manage Stress
Chronic stress can weaken the immune system and increase the risk of developing blood diseases. Implement stress reduction techniques, such as deep breathing exercises, meditation and yoga, or time in nature to help maintain a healthy mind and body.
- Practice Good Hygiene
Washing your hands regularly, keeping wounds clean, and avoiding contact with individuals who have contagious illnesses can reduce the risk of infection and help maintain a healthy immune system. Proper hygiene practices can also minimize the chance of developing blood infections and related complications.
Innovation and Progress
The development and approval of life-changing drugs like Polivy represent a significant milestone in the fight against blood diseases, particularly diffuse large B-cell lymphoma. These innovative treatments offer new hope for patients and their families and serve as a testament to the power of medical research and advancements in healthcare technology.
It is crucial to continue investing in research and development efforts to discover and refine novel treatments for blood diseases. By fostering a supportive environment for medical innovation, we can facilitate the creation of more groundbreaking therapies like Polivy, ultimately improving patient outcomes and transforming the treatment landscape for various blood disorders.